These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

831 related items for PubMed ID: 10066640

  • 1. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M, Salzberger B, Stiepel A, Hoetelmans R, Diehl V, Fätkenheuer G.
    Eur J Med Res; 1999 Feb 25; 4(2):54-8. PubMed ID: 10066640
    [Abstract] [Full Text] [Related]

  • 2. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
    Rockstroh JK, Altfeld M, Kupfer B, Kaiser R, Fätkenheuer G, Salzberger B, Schneweis KE, Spengler U.
    Eur J Med Res; 1999 Jul 28; 4(7):271-4. PubMed ID: 10425264
    [Abstract] [Full Text] [Related]

  • 3. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN, Feinberg J, Goodrich J, Pilson RS, Siemon-Hryczyk P.
    Antivir Ther; 2003 Feb 28; 8(1):37-42. PubMed ID: 12713062
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
    Langmann P, Zilly M, Weissbrich B, Schlör C, Väth T, Richter E, Klinker H.
    Eur J Med Res; 2000 Feb 28; 5(2):59-62. PubMed ID: 10720564
    [Abstract] [Full Text] [Related]

  • 5. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug 28; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 6. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.
    West Afr J Med; 2002 Aug 28; 21(2):83-6. PubMed ID: 12403023
    [Abstract] [Full Text] [Related]

  • 7. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F, Funk M, Linde R, Notheis G, Petropoulou T, Eberle J, Gürtler L, Belohradsky BH, Wintergerst U.
    Eur J Med Res; 2002 Jul 24; 7(7):330-4. PubMed ID: 12176683
    [Abstract] [Full Text] [Related]

  • 8. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.
    Clin Ther; 1999 Nov 24; 21(11):1853-63. PubMed ID: 10890257
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
    Wheat LJ, Farthing C, Cohen C, Pierone G, Lalezari J, Pilson RS, Siemon-Hryczyk P, TIDBID (NR15520/M61018) study team.
    Antivir Ther; 2002 Sep 24; 7(3):199-209. PubMed ID: 12487388
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J.
    Antivir Ther; 2003 Dec 24; 8(6):595-602. PubMed ID: 14760893
    [Abstract] [Full Text] [Related]

  • 11. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B, Frankfurt HIV Cohort.
    J Antimicrob Chemother; 2006 Nov 24; 58(5):1024-30. PubMed ID: 16956902
    [Abstract] [Full Text] [Related]

  • 12. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J.
    HIV Med; 2007 May 24; 8(4):226-33. PubMed ID: 17461850
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M, AVANTI Study Group.
    Antivir Ther; 2001 Jun 24; 6(2):127-34. PubMed ID: 11491417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.